OREANDA-NEWS. Redx Pharma, the drug discovery and development company, welcomes the publication today of a third paper prepared by The Review on Antimicrobial Resistance, chaired by Jim O'Neill. The paper focuses on the need to boost the development of new antibiotic drugs and sets out key proposals: to ensure that antibiotic R&D is commercially sustainable, to create a more stable commercial end market for antibiotics and to reduce barriers to drug development by lowering costs, improving the efficiency of research and lowering global regulatory barriers.

The report notes that there is a 'mismatch' between the increasing resistance to antibiotics and the lack of compounds currently being developed to combat AMR bacteria. Redx's Anti-Infectives division is currently at work to create such compounds.

 Dr Neil Murray, chief executive of Redx Pharma, commented:

"As the Review has highlighted, AMR is one of the critical issues facing global public health today, and it is only by addressing the fundamental challenges unique to antibiotic drug development that we have any chance of tackling this crisis. Redx's innovative partnership with the NHS is just one way that we are working to find solutions to the problem of AMR. We fully support the bold interventions proposed by the Review." 

About Redx Pharma Plc

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary, (patent-protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.  

About the Review on Antimicrobial Resistance

The UK Prime Minister commissioned the Review on Antimicrobial Resistance to address the growing global problem of drug-resistant infections. It is chaired by Jim O'Neill and supported by the Wellcome Trust and UK Government, but operates and speaks with full independence from both.